2017•HaematologicaOpen access

Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma: Updated results of a phase 1B/2 study.

MMatasar Matasar, AFHerrera Herrera, MKamdar Kamdar, AMehta Mehta, SAssouline Assouline, IFleury Fleury, TMKim Kim, WSKim Kim, FBosch Bosch, JRadford Radford, CRFlowers Flowers, LBu Bu, WJHong Hong, LHSehn Sehn

Open full text 3 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Bendamustine, Obinutuzumab, Follicular lymphoma, Rituximab, Medicine, Lymphoma, Oncology, Internal medicine